Positive Association of Serum Adipocyte Fatty Acid Binding Protein Level With Peripheral Artery Disease in Hemodialysis Patients.
Adipose Tissue
/ pathology
Ankle Brachial Index
/ methods
Atherosclerosis
/ epidemiology
Body Weight
Creatinine
/ analysis
Cross-Sectional Studies
Fatty Acid-Binding Proteins
/ blood
Female
Heart Disease Risk Factors
Humans
Kidney Failure, Chronic
/ blood
Male
Middle Aged
Peripheral Arterial Disease
/ blood
Predictive Value of Tests
Renal Dialysis
/ methods
Taiwan
/ epidemiology
Adipocyte fatty acid binding protein
Ankle-brachial index
Atherosclerosis
Hemodialysis
Peripheral arterial disease
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
revised:
10
08
2019
received:
13
04
2019
accepted:
20
08
2019
pubmed:
23
8
2019
medline:
15
12
2021
entrez:
22
8
2019
Statut:
ppublish
Résumé
Adipocyte fatty acid binding protein is positively associated with atherosclerosis. Peripheral arterial disease is associated with an increased mortality in hemodialysis patients. This study aimed to evaluate the relationship between serum adipocyte fatty acid binding protein levels and peripheral arterial disease by ankle-brachial index in hemodialysis patients. Among the 90 chronic hemodialysis recipients, 20 patients (22.2%) were in the low ankle-brachial index group who had a higher prevalence of diabetes, hyperlipidemia, statin use, older age, higher body fat mass, higher serum adipocyte fatty acid binding protein level, and lower serum creatinine level compared with patients in the control group. After statistical analysis, body fat mass (P = 0.006) and creatinine level (P = 0.018) were shown to be the independent predictors of adipocyte fatty acid binding protein level. Serum adipocyte fatty acid binding protein (P = 0.021) was found to be positively associated with peripheral arterial disease in hemodialysis patients.
Identifiants
pubmed: 31433560
doi: 10.1111/1744-9987.13431
doi:
Substances chimiques
FABP4 protein, human
0
Fatty Acid-Binding Proteins
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
300-306Subventions
Organisme : Department of S and T for Social Development
ID : MOST-104-2314-B-303-010
Informations de copyright
© 2019 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
Furuhashi M, Ishimura S, Ota H et al. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One 2011;6:e27356.
Sommer G, Ziegelmeier M, Bachmann A et al. Serum levels of adipocyte fatty acid-binding protein (AFABP) are increased in chronic haemodialysis (CD). Clin Endocrinol (Oxf) 2008;69:901-5.
Fowkes FG, Murray GD, Butcher I et al. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008;300:197-208.
Bhatt DL, Eagle KA, Ohman EM et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350-7.
Dua A, Lee CJ. Epidemiology of peripheral arterial disease and critical limb ischemia. Tech Vasc Interv Radiol 2016;19:91-5.
Yang Y, Ning Y, Shang W et al. Association of peripheral arterial disease with all-cause and cardiovascular mortality in hemodialysis patients: a meta-analysis. BMC Nephrol 2016;17:195.
Paraskevas KI, Kotsikoris I, Koupidis SA, Giannoukas AD, Mikhailidis DP. Ankle-brachial index: a marker of both peripheral arterial disease and systemic atherosclerosis as well as a predictor of vascular events. Angiology 2010;61:521-3.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
Tsai JP, Liou HH, Liu HM, Lee CJ, Lee RP, Hsu BG. Fasting serum fatty acid-binding protein 4 level positively correlates with metabolic syndrome in hemodialysis patients. Arch Med Res 2010;41:536-40.
Tsai JP, Wang JH, Lee CJ, Chen YC, Hsu BG. Positive correlation of serum adipocyte fatty acid binding protein levels with carotid-femoral pulse wave velocity in geriatric population. BMC Geriatr 2015;15:88.
Hsu BG, Lee CJ, Yang CF, Chen YC, Wang JH. High serum resistin levels are associated with peripheral artery disease in the hypertensive patients. BMC Cardiovasc Disord 2017;17:80.
Ferreira AC, Macedo FY. A review of simple, non-invasive means of assessing peripheral arterial disease and implications for medical management. Ann Med 2010;42:139-50.
Gerhard-Herman MD, Gornik HL, Barrett C et al. AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 2017;135:e726-79.
Jakovljevic B, Stojanov V, Lovic D, Paunovic K, Radosavljevic V, Tutic I. Obesity and fat distribution as predictors of aortoiliac peripheral arterial disease in middle-aged men. Eur J Intern Med 2011;22:84-8.
Chen J, Mohler ER, Xie D et al. Traditional and non-traditional risk factors for incident peripheral arterial disease among patients with chronic kidney disease. Nephrol Dial Transplant 2016;31:1145-51.
Xu A, Tso AW, Cheung BM et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007;115:1537-43.
Boord JB, Maeda K, Makowski L et al. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002;22:1686-91.
Makowski L, Boord JB, Maeda K et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001;7:699-705.
Furuhashi M, Tuncman G, Gorgun CZ et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007;447:959-65.
Tuncman G, Erbay E, Hom X et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 2006;103:6970-5.
El Husseny MW, Mamdouh M, Shaban S et al. Adipokines: potential therapeutic targets for vascular dysfunction in type II diabetes mellitus and obesity. J Diabetes Res 2017;2017:8095926.
Cabre A, Lazaro I, Girona J et al. Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin Chem 2008;54:181-7.
Stejskal D, Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome? Eur J Clin Invest 2006;36:621-5.
Erbay E, Babaev VR, Mayers JR et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med 2009;15:1383-91.
Park CG, Choi KM. Lipocalin-2, A-FABP and inflammatory markers in relation to flow-mediated vasodilatation in patients with essential hypertension. Clin Exp Hypertens 2014;36:478-83.
Das UN. Serum adipocytefatty acid-binding protein in the critically ill. Crit Care 2013;17:121.